Sign Up
Stories
FDA Fast Track for AdrenoMed's Enibarcimab
Share
HelixBind's RaPID/BSI Assay in Sepsis De...
Recce Pharmaceuticals Advances in Pharma...
Rising Demand Propels Alginate Market
In Vitro Toxicology Market Growth
Microbiological Testing Service Market I...
Point of Care Testing Market Set to Surp...
Overview
API
AdrenoMed AG secures FDA Fast Track for enibarcimab to treat septic shock, focusing on reducing mortality rates through precision medicine and biomarker-driven approach.
Ask a question
How could the success of enibarcimab influence future research and development in the treatment of septic shock?
How might the Fast Track designation expedite the approval process and impact patient access to enibarcimab?
What implications does the biomarker-driven approach have for personalized medicine in critical care?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage